Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
The red biotechnology market was valued at USD 410.54 Million in 2025. It is poised to grow at a CAGR of 6.20% during the forecast period of 2026-2035, and reach USD 749.20 Million by 2035. The growth in the market is supported by the rising global burden of cancer and rare genetic disorders, alongside accelerated regulatory approvals for cell and gene therapies, and continued advancements in CRISPR-based platforms and biopharmaceutical manufacturing.
Latest News on the Red Biotechnology Market (2026)
April 2026: Eli Lilly Acquires Kelonia Therapeutics in In Vivo Cell Therapy Push
Eli Lilly's acquisition of in vivo cell therapy developer Kelonia Therapeutics marked at least the sixth such buyout since March 2025 and the largest in total proceeds within the segment. The Wall Street Journal reported that the deal continues a near-weekly run of Lilly acquisitions, including the buyout of Ajax for its clinical-stage myelofibrosis therapy, reinforcing the centrality of cell and gene therapy assets to large-pharma pipeline strategy heading into the looming USD 170 billion patent cliff.
March 2026: Novartis–Avidity Biosciences USD 12 Billion Deal Advances Toward Close
Novartis's USD 12 billion acquisition of Avidity Biosciences advanced toward expected closing in the first half of 2026, alongside BioMarin Pharmaceutical's USD 4.8 billion buyout of Amicus Therapeutics announced 19 December 2025. As reported by Reuters, the combined dealmaking environment, supported by clearing U.S. healthcare policy overhangs and additional rate cuts, has positioned 2026 as one of the strongest investment windows for red biotechnology in recent decades according to industry analysts.
Key Market Trends and Insights
- By product type, cell and gene therapy products held nearly 24% market share in the forecast period.
- By end-user, the biopharmaceutical and biotechnology companies led the market in the historical period.
- North accounted for around 35% share of the market in the historical period.
Market Size and Forecast
- Market Size (2025): USD 410.54 Million
- Projected Market Size (2035): USD 749.20 Million
- CAGR (2026-2035): 6.20%
- Largest Market in 2025: North America
Compound Annual Growth Rate
6.2%
Value in USD Million
2026-2035
Red Biotechnology Market Overview
Red biotechnology covers the use of living cells and molecular tools to develop biologics, gene therapies, and precision diagnostics for human health, spanning biopharmaceutical production, gene therapy, pharmacogenomics, and genetic testing applications. The market was valued at USD 410.54 Million in 2025 and is poised to grow at a CAGR of 6.20%. The demand is driven by the rising burden of cancer, rare genetic disorders, and chronic disease, alongside expanding cell and gene therapy approvals.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Red Biotechnology Market Growth Drivers
Rising Burden of Cancer and Genetic Disorders is Set to Boost Red Biotechnology Market Expansion
The growing global burden of cancer and rare genetic disorders is the leading driver of demand for red biotechnology products. According to the World Health Organization, an estimated 20 million new cancer cases and 9.7 million cancer-related deaths occurred worldwide in 2022, with cases projected to exceed 35 million by 2050. This sustained burden underpins steady demand for biologics, gene therapies, monoclonal antibodies, and recombinant proteins across major healthcare markets globally.
Red Biotechnology Market Trends
A notable trend in the market is the shift toward CRISPR-based gene editing platforms and accelerated regulatory approvals supporting curative therapies for rare and genetic diseases.
Growing Adoption of CRISPR Gene Editing and Accelerated Approvals are Likely to Boost Red Biotechnology Market Growth
The increasing advancement of precision-targeted therapies and gene-editing technologies is emerging as a significant trend in the market. In May 2025, CRISPR Therapeutics reported positive Phase 1 results for CTX310 targeting ANGPTL3, demonstrating the in vivo gene editing platform's potential in cardiovascular disease, alongside ongoing CAR-T trials with CTX112 and CTX131. Such developments highlight the growing focus on innovative targeted treatment approaches, which are expected to accelerate research activities and support sustained market growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Red Biotechnology Market Segmentation
Market Breakup by Product Type
- Recombinant Therapeutic Proteins
- Vaccines
- Blood and Blood-Derived Products
- Personalized Medicines
- Diagnostic Kits and Reagents
- Cell and Gene Therapy Products
- Others
Market Breakup by Therapeutic Areas
- Oncology
- Autoimmune Disorders
- Rare Diseases & Genetic Disorders
- Infectious Diseases
- Chronic Diseases
- Others
Market Breakup by End-use
- Biopharmaceutical and Biotechnology Companies
- Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs)
- Academic and Research Institutes
- Hospitals and Diagnostic Laboratories
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Red Biotechnology Market Share
Personalized Medicines Segment to Strengthen Market by Product Type
Among all types, personalized medicines are expected to lead the market owing to the growing emphasis on precision therapeutics, targeted disease management, and genomics-based healthcare solutions. The increasing adoption of individualized treatment approaches in oncology and rare genetic disorders is further supporting segment expansion. For instance, in February 2025, personalized medicines are expected to lead the market owing to the growing emphasis on precision therapeutics, targeted disease management, and genomics-based healthcare solutions. The increasing adoption of individualized treatment approaches in oncology and rare genetic disorders is further supporting segment expansion. Such developments are expected to accelerate innovation and strengthen the long-term growth of the red biotechnology market.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Red Biotechnology Market Analysis by Region
North America is expected to dominate the global red biotechnology market, supported by advanced biologics manufacturing infrastructure, robust FDA-supported clinical trial activity, well-developed reimbursement frameworks, and a high concentration of leading developers. Asia Pacific is anticipated to grow at the fastest pace, supported by expanding biotech research clusters, hospital modernisation, and rising chronic disease burden across China, Japan, and India, while Europe maintains steady growth through orphan drug initiatives and CRISPR research collaborations.
Leading Players in the Red Biotechnology Market
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Hoffmann-La Roche
Roche, headquartered in Basel, Switzerland, supplies biologics through its Genentech subsidiary, including monoclonal antibodies and bispecific antibodies for oncology. In October 2024, Genentech’s inavolisib (Itovebi) received FDA approval for advanced HR-positive, HER2-negative breast cancer with PIK3CA mutation, advancing precision oncology.
Merck KGaA
Merck KGaA is a leading science and technology company actively supporting advancements in oncology and precision medicine through its healthcare and life science businesses. The company provides research tools, bioprocessing solutions, and testing services that support the development of targeted therapies. Its strong focus on molecular research, biomarker analysis, and therapeutic innovation strengthens its involvement in the market.
Pfizer, Inc.
Pfizer is a leading biopharmaceutical company actively advancing precision oncology therapies across targeted cancer treatment areas. The company’s BRAFTOVI® (encorafenib) combination regimen demonstrated significant efficacy in patients with BRAF V600E-mutant metastatic colorectal cancer, reinforcing Pfizer’s strong position in kinase-targeted therapeutics. Through its advanced oncology portfolio and continued investment in biomarker-driven therapies, Pfizer strengthens its position in the development of innovative biologics and personalized treatment solutions within the market.
Amgen Inc.
Amgen is a leading biotechnology company involved in developing targeted therapies and biologics across multiple therapeutic areas, including oncology and precision medicine. The company strengthens its presence in the market through its focus on advanced biologic research, targeted treatment strategies, and innovative therapeutic platforms. Its product portfolio, including Repatha® (evolocumab), reflects the company’s expertise in monoclonal antibody development and personalized treatment approaches supporting next-generation therapeutic innovation.
Other key players in the market are Regeneron Pharmaceuticals, Inc., Biogen Inc., AstraZeneca Plc., Takeda Pharmaceutical Company Ltd., Gilead Sciences, Inc., and Johnson & Johnson Services Inc.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Key Questions Answered in the Red Biotechnology Market Report
- What was the red biotechnology market value in 2025?
- What is the red biotechnology market forecast outlook for 2026-2035?
- What major factors aid the demand for the red biotechnology market?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market’s major drivers, opportunities, and restraints?
- What are the major red biotechnology market trends?
- Which application is expected to dominate the market segment?
- Which end-use is projected to lead the segment?
- Which region is anticipated to lead the global red biotechnology market?
- Who are the key players in the red biotechnology market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Pricing Plans
Upto 15% Off
USD
-
$5499 $4949
-
$3299 $2969
-
$6999 $5949
-
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Therapeutic Areas |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
